What Are Wall Street Analysts’ Target Price for Regeneron Pharmaceuticals Stock?

Regeneron Pharmaceuticals, Inc. (REGN) is a biotechnology company headquartered in Tarrytown, New York, with a market capitalization of around $62.3 billion. The company specializes in discovering, developing, manufacturing, and commercializing transformative medicines across a broad range of serious diseases, including eye diseases, allergy and inflammation, cancer, cardiovascular, neurological, infectious, hematologic, and rare diseases. A crucial competitive edge is its VelociSuite® technology platform, which accelerates the discovery and optimization of fully human and bispecific antibodies.

Regeneron Pharmaceuticals has experienced a challenging 2025 so far, with its shares declining 17.5% on a year-to-date (YTD) basis, falling starkly short of the 9.9% YTD gain of the S&P 500 Index ($SPX). Over the past 52 weeks, REGN stock dipped by 51%, whereas the benchmark climbed by 15.1%.